test

Phase I Study of BVD-523 in Patients with Advanced Malignancies

Conditions

Melanoma, skin

What is the purpose of this trial?

To define the safety and tolerability of BVD-523 in patients with advanced malignancies by determining the dose-limiting toxicities (DLT), the maximum tolerated dose (MTD), and the recommended Phase 2 Dose (RP2D).


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
BioMed Valley Discoveries, Inc.
Dates:
07/18/2014
Last Updated:
Study HIC#:
1303011687